The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
Open accessAbstract
Thirty-five years of research on p53 gave rise to more than 68,000 articles and reviews, but did not allow the uncovering of all the mysteries that this major tumor suppressor holds. How p53 handles the different signals to decide the appropriate cell fate in response to a stress and its implication in tumorigenesis and cancer progression remains unclear. Nevertheless, the uncovering of p53 isoforms has opened new perspectives in the cancer research field. Indeed, the human TP53 gene encodes not only one but at least twelve p53 protein isoforms, which are produced in normal tissues through alternative initiation of translation, usage of alternative promoters, and alternative splicing. In recent years, it became obvious that the different p53 isoforms play an important role in regulating cell fate in response to different stresses in normal cells by differentially regulating gene expression. In cancer cells, abnormal expression of p53 isoforms contributes actively to cancer formation and progression, regardless of TP53 mutation status. They can also be associated with response to treatment, depending on the cell context. The determination of p53 isoform expression and p53 mutation status helps to define different subtypes within a particular cancer type, which would have different responses to treatment. Thus, the understanding of the regulation of p53 isoform expression and their biological activities in relation to the cellular context would constitute an important step toward the improvement of the diagnostic, prognostic, and predictive values of p53 in cancer treatment. This review aims to summarize the involvement of p53 isoforms in cancer and to highlight novel potential therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
p53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
Dumont, P., Leu, J. I.-J., Della Pietra, A. C., George, D. L., & Murphy, M. (2003) · Nature Genetics · doi:10.1038/ng1093 · Cited by 1,273
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
Death Signal-induced Localization of p53 Protein to Mitochondria
Marchenko, N. D., Zaika, A., & Moll, U. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16202 · Cited by 901
p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes
Caelles, C., Helmberg, A., & Karin, M. (1994) · Nature · doi:10.1038/370220a0 · Cited by 843
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Self-citationWild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734
A transcriptionally active DNA-binding site for human p53 protein complexes.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., & Shay, J. W. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2866 · Cited by 732
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
Wild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 692
High levels of p53 protein in UV-irradiated normal human skin.
Hall, P. A., Ph, M., Hd, M., Dover, R., & Lane, D. P. (1993) · PubMed · Cited by 673
Modulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586
Hinds, P., Finlay, C., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 577
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53
Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 552
Murray-Zmijewski, F., Lane, D. P., & Bourdon, J.-C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401914 · Cited by 523
Self-citationFlores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.019 · Cited by 502
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells
Reich, N. C., & Levine, A. J. (1984) · Nature · doi:10.1038/308199a0 · Cited by 494
Posttranslational Modification of p53: Cooperative Integrators of Function
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 483
Transcription-independent pro-apoptotic functions of p53
Moll, U. M., Wolff, S., Speidel, D., & Deppert, W. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.007 · Cited by 468
DNA damage checkpoints in stem cells, ageing and cancer
Sperka, T., Wang, J., & Rudolph, K. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3420 · Cited by 393
Sheikh, M. S., Burns, T. F., Huang, Y., Wu, G. S., Amundson, S. A., Brooks, K., Fornace, A. J., & El‐Deiry, W. S. (1998) · PubMed · Cited by 360
Maddocks, O. D. K., & Vousden, K. H. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0735-5 · Cited by 355
p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336
Self-citationp63 and p73, the ancestors of p53
Dotsch, V., Bernassola, F., Coutandin, D., Candi, E., & Melino, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004887 · Cited by 326
Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus
Mowat, M., Cheng, A., Kimura, N., Bernstein, A., & Benchimol, S. (1985) · Nature · doi:10.1038/314633a0 · Cited by 320
Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhraeus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 306
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.
Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L., & Benchimol, S. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02287.x · Cited by 299
Functional regulation of p73 and p63: development and cancer
Melino, G. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.10.004 · Cited by 278
Li, M., He, Y., Dubois, W., Wu, X., Shi, J., & Huang, J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.020 · Cited by 264
Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 263
The p53 family: guardians of maternal reproduction
Levine, A. J., Tomasini, R., McKeon, F. D., Mak, T. W., & Melino, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3086 · Cited by 252
Regulation of Human p53 Activity and Cell Localization by Alternative Splicing
Ghosh, A., Stewart, D., & Matlashewski, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.7987-7997.2004 · Cited by 221
Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies.
Mercer, W. E., Avignolo, C., & Baserga, R. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.2.276 · Cited by 218
Levine, A. J. (2009) · Virology · doi:10.1016/j.virol.2008.09.034 · Cited by 212
Two internal ribosome entry sites mediate the translation of p53 isoforms
Ray, P. S., Grover, R., & Das, S. (2006) · EMBO reports · doi:10.1038/sj.embor.7400623 · Cited by 208
TP53 family members and human cancers
Bénard, J., Douc-Rasy, S., & Ahomadegbe, J.-C. (2003) · Human Mutation · doi:10.1002/humu.10172 · Cited by 206
The Isoforms of the p53 Protein
Khoury, M. P., & Bourdon, J.-C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000927 · Cited by 191
Self-citationReactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Goldstein, I., Marcel, V, Olivier, M., Oren, M., Rotter, V, & Hainaut, P. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2010.63 · Cited by 167
p53 Isoforms: An Intracellular Microprocessor?
Khoury, M. P., & Bourdon, J.-C. (2011) · Genes & Cancer · doi:10.1177/1947601911408893 · Cited by 159
Self-citationRecent Advances in the Therapeutic Perspectives of Nutlin-3
Secchiero, P., Bosco, R., Celeghini, C., & Zauli, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222586 · Cited by 158
Garritano, S., Gemignani, F., Palmero, E. I., Olivier, M., Martel-Planche, G., Le Calvez-Kelm, F., Brugiéres, L., Vargas, F. R., Brentani, R. R., Ashton-Prolla, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21151 · Cited by 153
A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint
Rohaly, G., Chemnitz, J., Dehde, S., Nunez, A. M., Heukeshoven, J., Deppert, W., & Dornreiter, I. (2005) · Cell · doi:10.1016/j.cell.2005.04.032 · Cited by 152
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage
Aoubala, M., Murray-Zmijewski, F., Khoury, M. P., Fernandes, K., Perrier, S., Bernard, H., Prats, A., Lane, D. P., & Bourdon, J. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.91 · Cited by 136
Self-citationThe p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129
Immunologically Distinct p53 Molecules Generated by Alternative Splicing
Arai, N., Nomura, D., Yokota, K., Wolf, D., Brill, E., Shohat, O., & Rotter, V. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.9.3232 · Cited by 128
Heterochromatin silencing of p53 target genes by a small viral protein
Soria, C. T., Estermann, F. E., Espantman, K. C., & O’Shea, C. C. (2010) · Nature · doi:10.1038/nature09307 · Cited by 127
Novel Dyskerin-Mediated Mechanism of p53 Inactivation through Defective mRNA Translation
Montanaro, L., Calienni, M., Bertoni, S., Rocchi, L., Sansone, P., Storci, G., Santini, D., Ceccarelli, C., Taffurelli, M., Carnicelli, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4024 · Cited by 126
Δ160p53 is a novel N‐terminal p53 isoform encoded by Δ133p53 transcript
Marcel, V., Perrier, S., Aoubala, M., Ageorges, S., Groves, M. J., Diot, A., Fernandes, K., Tauro, S., & Bourdon, J.-C. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.10.005 · Cited by 125
Self-citationAvery‐Kiejda, K. A., Zhang, X. D., Adams, L. J., Scott, R. J., Vojtěšek, B., Lane, D. P., & Hersey, P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1422 · Cited by 122
Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms
Grover, R., Ray, P. S., & Das, S. (2008) · Cell Cycle · doi:10.4161/cc.7.14.6271 · Cited by 110
Bourdon, J., Khoury, M. P., Diot, A., Baker, L., Fernandes, K., Aoubala, M., Quinlan, P., Purdie, C. A., Jordan, L. B., Prats, A., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2811 · Cited by 110
Self-citationDutertre, M., Sanchez, G., Barbier, J., Corcos, L., & Auboeuf, D. (2011) · RNA Biology · doi:10.4161/rna.8.5.16016 · Cited by 102
Δ40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCsPreprint
Ungewitter, E. K., & Scrable, H. J. (2010) · Genes & Development · doi:10.1101/gad.1987810 · Cited by 101
The human tumour suppressor gene p53 is alternatively spliced in normal cells.
Flaman, J., Waridel, F., Estreicher, A., Vannier, A., Limacher, J., Gilbert, D., Iggo, R. D., & Frébourg, T. (1996) · PubMed · Cited by 98
Regulation of Programmed Cell Death by the P53 Pathway
Kuribayashi, K., & El‐Deiry, W. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_10 · Cited by 95
Ånensen, N., Oyan, A. M., Bourdon, J., Kalland, K. H., Bruserud, Ø., & Gjertsen, B. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1970 · Cited by 94
Self-citationWei, J., Noto, J. M., Zaika, E. I., Romero–Gallo, J., Correa, P., El-Rifai, W. M., Peek, R. M., & Zaika, A. I. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205664109 · Cited by 92
The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA
Weingarten-Gabbay, S., Khan, D., Liberman, N., Yoffe, Y., Bialik, S., Das, S., Oren, M., & Kimchi, A. (2013) · Oncogene · doi:10.1038/onc.2012.626 · Cited by 91
Pehar, M., O’Riordan, K. J., Burns‐Cusato, M., Andrzejewski, M. E., del Alcazar, C. R. G., Bürger, C., Scrable, H. J., & Puglielli, L. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00547.x · Cited by 89
Isolation of a Full-Length Mouse cDNA Clone Coding for an Immunologically Distinct p53 Molecule
Wolf, D., Harris, N., Goldfinger, N., & Rotter, V. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.1.127 · Cited by 83
The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression
Bernard, H., Garmy-Susini, B. H., Ainaoui, N., Berghe, L. V. D., Peurichard, A., Javerzat, S., Bikfalvi, A., Lane, D. P., Bourdon, J., & Prats, A. (2012) · Oncogene · doi:10.1038/onc.2012.242 · Cited by 83
Self-citationHofstetter, G., Berger, A., Fiegl, H., Slade, N., Zorić, A., Holzer, B., Schuster, E., Möbus, V. J., Reimer, D., Daxenbichler, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.482 · Cited by 82
Expression of p53 isoforms in squamous cell carcinoma of the head and neck
Boldrup, L., Bourdon, J., Coates, P. J., Sjöström, B., & Nylander, K. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.019 · Cited by 81
Self-citationTerrier, O., Textoris, J., Carron, C., Marcel, V., Bourdon, J., & Rosa‐Calatrava, M. (2013) · Journal of General Virology · doi:10.1099/vir.0.049528-0 · Cited by 79
Self-citationMarcel, V., Vijayakumar, V., Fernandez‐Cuesta, L., Hafsi, H., Sagne, C., Hautefeuille, A. H., Olivier, M., & Hainaut, P. L. (2010) · Oncogene · doi:10.1038/onc.2010.26 · Cited by 79
Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform
Slatter, T. L., Hung, N. A., Campbell, H. G., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A. R., et al. (2011) · Blood · doi:10.1182/blood-2010-11-321851 · Cited by 78
Munroe, D. G., Rovinski, B., Bernstein, A., & Benchimol, S. (1988) · PubMed · Cited by 72
Annexin A2 and PSF proteins interact with p53 IRES and regulate translation of p53 mRNA
Arandkar, S., Lal, R., Khan, D., & Das, S. (2012) · RNA Biology · doi:10.4161/rna.22707 · Cited by 71
Human tumor suppressor p53 and DNA viruses
Collot-Teixeira, S., Bass, J., Denis, F., & Ranger‐Rogez, S. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.431 · Cited by 69
Ånensen, N., Hjelle, S. M., Belle, W. V., Haaland, I., Silden, E., Bourdon, J., Hovland, R., Taskén, K., Knappskog, S., Lønning, P. E., et al. (2011) · Oncogene · doi:10.1038/onc.2011.348 · Cited by 67
Self-citationNeubauer, A., He, M., Schmidt, C. A., Huhn, D., & Liu, E. T. (1993) · PubMed · Cited by 60
Δ40 Isoform of p53 Controls β-Cell Proliferation and Glucose Homeostasis in Mice
Hinault, C., Kawamori, D., Liew, C. W., Maier, B., Hu, J., Keller, S. R., Mirmira, R. G., Scrable, H. J., & Kulkarni, R. (2011) · Diabetes · doi:10.2337/db09-1379 · Cited by 57
Marcel, V., Petit, I., Murray-Zmijewski, F., de Rugy, T. G., Fernandes, K., Meuray, V., Diot, A., Lane, D. P., Aberdam, D., & Bourdon, J. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.152 · Cited by 55
Self-citationp53 isoform profiling in glioblastoma and injured brain
Takahashi, R., Giannini, C., Sarkaria, J. N., Schroeder, M., Rogers, J., Mastroeni, D., & Scrable, H. J. (2012) · Oncogene · doi:10.1038/onc.2012.322 · Cited by 52
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
Hofstetter, G., Berger, A., Schuster, E., Wolf, A. M., Hager, G., Vergote, I. B., Cadron, I., Sehouli, J., Braicu, E. I., Mahner, S., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.433 · Cited by 51
NUTTHASIRIKUL, N., Limpaiboon, T., Leelayuwat, C., Patrakitkomjorn, S., & Jearanaikoon, P. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1818 · Cited by 48
The N-Terminally Truncated p53 Isoform △40p53 Influences Prognosis in Mucinous Ovarian Cancer
Hofstetter, G., Berger, A., Berger, R., Zorić, A., Braicu, E. I., Reimer, D., Fiegl, H., Marth, C., Zeimet, A. G., Ulmer, H., et al. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31823ca031 · Cited by 46
Expression of p53 isoforms in renal cell carcinoma.
Song, W., Huo, S.-W., Lü, J., et al. (2009) · PubMed · Cited by 43
Effect of a natural mutation in the 5′ untranslated region on the translational control of p53 mRNA
Khan, D., Sharathchandra, A., Ponnuswamy, A., Grover, R., & Das, S. (2012) · Oncogene · doi:10.1038/onc.2012.422 · Cited by 42
Ding, Y. (1999) · DNA Research · doi:10.1093/dnares/6.5.347 · Cited by 37
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer
Marabese, M., Marchini, S., Marrazzo, E., Mariani, P., Cattaneo, D., Fossati, R., Compagnoni, A., Signorelli, M., Moll, U. M., Codegoni, A. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.011 · Cited by 37
The p53 isoforms are differentially modified by Mdm2
Camus, S., Ménendez, S., Fernandes, K., Kua, N., Liu, G., Xirodimas, D. P., Lane, D. P., & Bourdon, J. (2012) · Cell Cycle · doi:10.4161/cc.20119 · Cited by 36
Self-citationInfluenza A Viruses Control Expression of Proviral Human p53 Isoforms p53β and Δ133p53α
Terrier, O., Marcel, V., Cartet, G., Lane, D. P., Lina, B., Rosa‐Calatrava, M., & Bourdon, J. (2012) · Journal of Virology · doi:10.1128/jvi.07143-11 · Cited by 34
Self-citationExpression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53null Cell Lines
Silden, E., Hjelle, S. M., Wergeland, L., Sulen, A., Andresen, V., Bourdon, J., Micklem, D., McCormack, E., & Gjertsen, B. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056276 · Cited by 33
Self-citationGatekeeper Between Quiescence and Differentiation
Quadrato, G., & Giovanni, S. D. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-398309-1.00005-6 · Cited by 28
Glucose Tolerance in Mice is Linked to the Dose of the p53 Transactivation Domain
Franck, D., Tracy, L., Armata, H. L., Delaney, C. L., Jung, D. Y., Ko, H. J., Ong, H., Kim, J. K., Scrable, H. J., & Sluss, H. K. (2012) · Endocrine Research · doi:10.3109/07435800.2012.735735 · Cited by 27
p53 Protein Isoforms: Key Regulators in the Front Line of Pathogen Infections?
Terrier, O., Bourdon, J., & Rosa‐Calatrava, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003246 · Cited by 19
Self-citation
Cited by
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826
Major apoptotic mechanisms and genes involved in apoptosis
Kiraz, Y., Adan, A., Kartal Yandim, M., & Baran, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5035-9 · Cited by 582
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & Müller, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 291
Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Metadata
- Authors
- Bourdon, J.-C., Surget, S., & Khoury, M. P.
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-12
- Volume
- 7
- Pages
- 57
- ISSN
- 1178-6930 (ISSN-L)
- OpenAlex
- W2001108463
- Cited by
- 382
- References
- 105
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.